Skip to content
Medical Health Aged Care

AUSTRALIAN WORLD-FIRST TRIAL OFFERS NEW HOPE FOR TYPE 1 DIABETES

St Vincent's Institute of Medical Research 4 mins read
Professor Thomas Kay and Professor Helen Thomas

Researchers at St Vincent’s Institute of Medical Research (SVI) in Melbourne have shown that a commonly prescribed rheumatoid arthritis drug can stop the progression of type 1 diabetes. 

The world-first human trial, published today in the New England Journal of Medicine and led by SVI’s Professor Thomas Kay, showed that a drug called baricitinib can safely and effectively preserve the body’s own insulin production and suppress the progression of type 1 diabetes in people who initiated treatment within 100 days of diagnosis.   

“When type 1 diabetes is first diagnosed there is a substantial number of insulin-producing cells still present. We wanted to see whether we could protect further destruction of these cells by the immune system. We showed that baricitinib is safe and effective at slowing the progression of type 1 diabetes in people who have been recently diagnosed,” said Professor Kay. 

This ground-breaking research shows promise as the first disease-modifying treatment of its kind for type 1 diabetes that can be delivered as a tablet. 

“It is tremendously exciting for us to be the first group anywhere in the world to test the efficacy of baricitinib as a potential type 1 diabetes treatment,” said Professor Kay. 

“Up until now, people with type 1 diabetes have been reliant on insulin delivered via injection or infusion pump. Our trial showed that, if started early enough after diagnosis, and while the participants remained on the medication, their production of insulin was maintained. People with type 1 diabetes in the trial who were given the drug required significantly less insulin for treatment.”  

Management of the lifelong autoimmune disease is incredibly burdensome on those diagnosed and their families, requiring meticulous glucose monitoring and insulin administration day and night to stay alive.  

Up until insulin’s discovery more than 100 years ago, type 1 diabetes was a fatal condition. Despite insulin’s life-saving role, the therapy itself is potentially dangerous if too much or too little is administered, and the condition still comes with long-term complications, including heart attack and stroke, vision impairment, kidney disease and nerve damage.  

“We are very optimistic that this treatment will become clinically available. This would be a huge step-change in how type 1 diabetes is managed and we believe it shows promise as a fundamental improvement in the ability to control type 1 diabetes,” said Professor Helen Thomas, preclinical lead on the trial. 

The clinical trial was funded by JDRF, the leading type 1 diabetes research, advocacy and community programs organisation, including through the JDRF Type 1 Diabetes Clinical Research Network. Partners included The Royal Melbourne Hospital, St Vincent’s Hospital Melbourne, The Royal Children’s Hospital and The Women’s and Children’s Hospital in Adelaide. 

ENDS
 
Explainer animation: https://youtu.be/0LU41oZSkak

 


Key Facts:

The results of the BANDIT trial have been published in the New England Journal of Medicine.

 

In the past 12 months, only 4 papers accepted for publication in the NEJM have been by by Australian research groups.

 

About type 1 diabetes  

  • Type 1 diabetes is an autoimmune disease in which the body’s immune system mistakenly attacks and kills the cells in the pancreas that produce insulin. 

  •  
  • People with type 1 diabetes are dependent on externally administered insulin in order to survive. 

  •  
  • Type 1 diabetes is most commonly diagnosed in children, but adults can also be diagnosed with the disease. 

  •  
  • More than 130,000 Australians have type 1 diabetes – we have one of the highest rates of type 1 diabetes in the world. In 2022, around 4,000 people were newly diagnosed with type 1 diabetes in Australia. 

  •  
  • The estimated health care cost in Australia for treating people with type 1 diabetes in 2012 was $570 million annually (latest figures available). 

 

More about the science 

  1. On average, bringing a new drug to market costs $2-3 billion and takes more than 13 years of intense study and clinical trials. Many drugs fall at one or other of the hurdles put before them – they have unintended side effects, or are toxic, or patients don’t show the benefits that have been seen in animal models of disease. Because of the great investment in time, money and resources spent on getting a drug to the clinic, researchers are increasingly combing through the medicine chest of approved drugs to identify those that might work for a different indication. 

  1.  
  2. The randomised, double-blind, placebo-controlled human trial of the drug baricitinib monitored the blood glucose and insulin production of 91 participants over the course of one year.  Of these, 60 were given baricitinib and 31 were given a placebo. All trial participants were aged between 10 years old and 30 years old and started on the trial within 100 days of having been diagnosed with type 1 diabetes. Participants continued with their prescribed insulin therapy throughout the duration of the study. Researchers monitored participants’ total daily dose of insulin, the amount of insulin produced endogenously (by their own pancreas), their blood glucose levels, and their HbA1C levels. HbA1c, or glycated haemoglobin, is a measure of average blood glucose (sugar) levels for the last two to three months. 

  1.  
  2. Baricitinib blocks an enzyme which normally helps to transmit signals that regulate the immune system and inflammation. The drug is currently prescribed for the treatment of rheumatoid arthritis, which is another autoimmune disease. It is thought that the drug similarly dampens down the immune response that is mounted against insulin-producing cells in people with newly diagnosed type 1 diabetes, thus delaying the onset of full-blown symptoms of the disease, improving glucose control and reducing potential for detrimental longer term health effects.  

  1.  
  2. The attached videos demonstrate the ‘life and death of a beta cell’, and what happens in the lab setting when a similar drug is used in cell culture with insulin-producing cells incubated together with immune cells. In the first video, without the treatment, the immune cells attack and kill the insulin-producing cells. When the drug is included in the second video, the immune cells are disabled and are unable to kill the insulin-producing cells.  


About us:

St Vincent’s Institute of Medical Research (SVI) is a Melbourne-based, independent medical research institute that conducts biomedical research into the cause, prevention and treatment of high-impact diseases such as cancer, heart disease, diabetes, obesity, bone diseases and Alzheimer’s. SVI is affiliated with St. Vincent’s Hospital and the University of Melbourne. www.svi.edu.au. 


Contact details:

Samantha Porter, +61 458460334

Media

More from this category

  • Medical Health Aged Care
  • 29/05/2024
  • 11:54
NDARC

Long-term prescription opioid use after hospital declining: study

UNSW Sydney medical researchers have shed light on post-hospital prescription opioid use. A large, linked data study has detailed the scale of prescription opioid…

  • Contains:
  • Medical Health Aged Care
  • 29/05/2024
  • 11:45
Cleo Diagnostics Limited ASX.COV

Cleo’s Ovarian Cancer Blood Test Outperforms Current Clinical Benchmark

Highlights A benchmarking study comparing CLEO’s ovarian cancer blood test against ultrasound has been published in scientific journal “Cancers” The study confirmed that CLEO’s initial test for the surgical triage market:– Significantly outperforms current clinical workflows that use CA125 and ultrasound to predict malignancy;– Correctly detected 90% of early-stage cancers compared to only 50% using standard workflows; and– Can be easily adopted for use into clinical practice. The superior performance of CLEO’s test now compared to all current routine clinical tools shows the significant global potential for the test in clinical decision making prior to surgical intervention. MELBOURNE, AUSTRALIA, 29…

  • Medical Health Aged Care
  • 29/05/2024
  • 05:00
Dementia Australia

De-escalation VR training for behavioural emergencies set to revolutionise dementia education – on show today at Adelaide Convention Centre

In Adelaide today Dementia Australia unveiled D-Esc, a new innovative virtual reality (VR) training workshop for de-escalating a behavioural emergency in a care setting. D-Esc provides an immersive simulation, designed for frontline and health care professionals, to adopt an interactive approach to de-escalation training. Participants will build empathy and understanding towards people with dementia, with the aim to reduce the use of restrictive practices and the number and severity of dangerous incidents in care. Dementia Australia Executive Director Services, Advocacy and Research Dr Kaele Stokes said this new workshop provides training which is integral to the safety and professional development…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.